{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
  "id": "02964020",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
  "summary": "**June Quarter FY 2026 Investor Update - Key Highlights:**  \n\n- **Combogesic IV\u00ae launch in Canada** begins this month, targeting non-opioid pain management in a market growing at 6.1% CAGR (forecast to reach US$1.88B by 2030).  \n- **US Maxigesic licensing agreement extended with Hikma Pharmaceuticals**: Restructured profit-sharing (quarterly payments) and expanded marketing rights for Combogesic IV/Rapid.  \n- **R&D pipeline milestones**:  \n  - Pre-IND filed for antibiotic eyedrop (targeting MRSA-resistant infections); IND targeted by year-end.  \n  - Pre-IND for Strawberry Birthmarks topical treatment and IND for novel iron injection planned by year-end.  \n  - Added improved formulation project (US$180M niche market potential).  \n- **Paediatric Maxigesic IV study** to commence, addressing unmet needs in hospital pain management.  \n- **Global expansion**: Further OTC and in-licensed product launches planned in FY26 across Canada, Singapore, Hong Kong, and other markets.  \n\n**No material financial data (e.g., cash balance) disclosed.**",
  "usage": {
    "prompt_tokens": 2424,
    "completion_tokens": 243,
    "total_tokens": 2667,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T22:18:04.740111"
}